The EuroMena Funds Successfully Concluded Its Nineteenth Deal by Investing in Retail Holding a Leading Diversified Retailer in Morocco
EuroMena is pleased to announce the acquisition of a minority stake of Retail Holding SA (the “Group”), a leading Moroccan Retailer. Proceeds of the investment will mainly be used to fund the expansion of the Group.
The Group was established in the mid-80s by Mr. Zouhair Bennani, initially as a single supermarket in Rabat, operating under the Hyper brand. Over the years the Group grew substantially, and is now one of the major retailers in Morocco. Retail Holding is the franchisee for French giant Carrefour, apparel retailer Kiabi, Virgin Megastore and fast food chain Burger King. The Group recently started its expansion to Africa by taking the control of CDCI (Compagnie de Distribution de Côte d’Ivoire), the second largest player in food distribution in Ivory Coast. It is now the number one player in the supermarket segment, the pioneer and only player in the hypercash segment, and a leader in the commercial real estate sector.
Furthermore, the Group is well positioned for a healthy growth in the coming five years as it will capitalize on the shifting retail landscape in Morocco, where the government is promoting the development of large modern retail spaces, and on the sub-Saharan expansion opportunities.
Gilles de Clerck, Executive Partner of The EuroMena Funds, mentioned on the occasion, “EuroMena is proud to join the retail leader at such an important time for the group, in which it is rapidly expanding in Morocco and regionally, led by an experienced management team”.
Paul Khoury, Partner of The EuroMena Funds, added, “We are confident that the group is well positioned for a healthy growth in the coming years, with the government promoting the development of modern retail and a shift in consumer behaviour towards the growing channel”.
Zouhair Bennani, Chief Executive Officer of Best Financière, stated, “We are proud to welcome The EuroMena Funds, a leading private equity firm invested in the MEA (Middle East and Africa) region, as a shareholder of the group and in supporting the development of the company, especially its Label’Vie and Compagnie de distribution de Côte d’Ivoire subsidiaries, both leaders in their respective markets”.
EuroMena has accumulated significant experience in the retail sector through its investments in Khoury Home, the leading retailer of home appliances and electronics in Lebanon, and the Indigo Company, a Tunis based apparel retail of international brands with a strong presence in Morocco and Algeria. In line with its strategy, EuroMena will assist the top management of Retail Holding in its growth strategy in the North and Sub-Saharen Africa regions, in which the Fund enjoys a wide network and significant market knowledge.
This transaction is the fourth investment of EuroMena III following the investments in Elephant (FMCG, Nigeria), in Indigo Company (apparel retail franchising, Tunisia, Morocco and Algeria), and in Credit Libanais (banking, Lebanon).
The EuroMena Fund Management Team has raised more than USD 350 million to date from prominent investors, and has closed more than 25 investments and divestments, within its target region. In June 2016, the Group completed the closing of its third fund, EuroMena III, for a total of USD 150 million, backed by commitments of top tier European institutions such as the European Investment Bank (EIB), the French Public Wealth Funds (Proparco), and the UK’s Development Finance Institution (CDC Group), the International Finance Corporation (IFC), The German Investment and Development Corporation (DEG), as well as high net worth individuals, and family offices.
EuroMena III’s mission is to invest in high growth local companies in the Middle East, North Africa and Sub-Saharan Africa, turn them into Regional Leading Groups, and prepare them for a profitable exit within a timeframe of 3-5 years.
In addition, The EuroMena Funds are planning on launching a Levant SME Fund and a MEA Debt Fund within the coming 6 months.
*Source: ME NewsWire
Denise Yamine, +97444283111
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Andersen Global Expands Presence in Germany with Addition of Thierhoff Müller & Partner13.12.2017 08:01 | Pressemelding
Andersen Global is proud to announce an expanded presence in Germany as Thierhoff Müller & Partner, a tax and legal firm with offices in Leipzig and Frankfurt, combines its practice with Andersen Tax & Legal in Germany. Through its German member firms, Andersen Tax & Legal and Alegis Steuerberatungsgesellschaft mbH, Andersen Global now has more than 65 professionals focused on providing tax and legal services and business advice across five locations in Germany, including Cologne, Dusseldorf, and Merzig. “Thierhoff Müller is highly regarded in complex restructuring matters. Together with our existing legal and tax practice, we will be able to increase our service offerings for our clients,” said Stefan Kraus, Managing Partner of Andersen Tax & Legal in Germany. “We are dedicated to providing outstanding service and are adding additional competencies in tax and legal such as corporate r
Aprecia Pharmaceuticals and Cycle Pharmaceuticals Partner to Develop 3D-Printed Orphan Drugs13.12.2017 08:00 | Pressemelding
Aprecia Pharmaceuticals, LLC (“Aprecia”), The 3DP Pharmaceutical Company, and Cycle Pharmaceuticals, Ltd. (“Cycle”) today announced they have signed a partnership agreement to develop and commercialize orphan drugs using three-dimensionally printed (“3DP”) technology. The planned products will deliver quality-of-life improvements versus existing, approved orphan drugs, and will achieve this by utilizing Aprecia’s proprietary 3DP ZipDose® Technology platform. ZipDose® is the only three-dimensional printing technology used in a pharmaceutical drug product approved by the U.S. Food and Drug Administration. Antonio Benedetti, CEO of Cycle commented: “Many rare disease patients do not have a treatment option at all. For those rare diseases where there is an approved pharmaceutical treatment, patients continue to be burdened by sub-optimal drug formulations. Aprecia’s
Group Vivendi Africa Deploys Netcracker OSS to Enhance Service Management as it Expands Across the Continent12.12.2017 16:07 | Pressemelding
Netcracker Technology announced today that its OSS suite was selected and deployed to support the long-term growth strategy of Group Vivendi Africa (GVA). GVA is a newly formed affiliate of the French-based multinational conglomerate Vivendi with the goal to deploy and operate a fiber network across Africa. Netcracker's OSS will be used as a consolidated solution to identify service availability across GVA's operating countries and then fulfill and provision those services to customers. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171212005937/en/ Netcracker's highly productized, out-of-the-box applications enabled the OSS suite to be deployed in seven months, meeting GVA's demand to leverage an integrated service fulfillment and inventory solution that could satisfy its long-term growth expectations, as well as s
Philip Morris International Releases Latest Scientific Update for Smoke-Free Products on Clinical Program12.12.2017 15:23 | Pressemelding
Philip Morris International Inc. (PMI) (NYSE/Euronext Paris: PM) today released its latest Scientific Update for Smoke-Free Products, a regular publication on its research efforts to develop and assess a range of smoke-free alternatives to cigarettes. The latest issue of the Scientific Update can be found at this link. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171212005891/en/ Philip Morris International Releases Latest Scientific Update for Smoke-Free Products on Clinical Program (Photo: Business Wire) This issue of the Scientific Update provides a closer look at some of the principles and practices on which PMI’s scientific assessment program is built. Director Medical Affairs Dr. Patrick Picavet describes specific examples from PMI’s clinical program that highlight the company’s
Murex to Offer MX.3 Risk, Trading and Post-Trade Solutions on the AWS Cloud12.12.2017 14:00 | Pressemelding
Murex, an industry leader in trading, risk management and processing solutions for capital markets, announced they will run their MX.3 technology platform on Amazon Web Services, Inc. (AWS). With the acceleration of cloud adoption in capital markets, Murex and AWS agreed to collaborate to help clients migrate their Murex application workloads to the AWS Cloud. Murex clients are looking to consolidate more and more of their capital markets activity on the MX.3 platform and this means their need for infrastructure is increasing. New regulatory requirements are also driving financial organizations to use cloud to scale up their computing capacity. Murex is collaborating with AWS to meet the demand from clients to support deployment of the Murex offering on the AWS Cloud. Murex is working on the validation of a range of deployment scenarios, from using AWS Cloud for bursting grid
Darzalex®▼(daratumumab) Combination Regimen Significantly Improved Outcomes for Newly Diagnosed Multiple Myeloma Patients who are Transplant Ineligible12.12.2017 13:33 | Pressemelding
Janssen-Cilag International NV (“Janssen”) today announced data from the Phase 3 ALCYONE study, showing Darzalex® (daratumumab) in combination with bortezomib, melphalan and prednisone (VMP) significantly improved clinical outcomes, including reducing the risk of disease progression or death by 50 percent, in patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation (ASCT).1 These data were accepted as a late-breaking abstract (LBA) for presentation at the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta, today at 7:30 a.m. ET (Abstract #LBA-4).1 Study findings were simultaneously published in the New England Journal of Medicine (NEJM) . 2 Daratumumab is currently indicated for use in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom